Article
Oncology
Pietro Rosellini, Samuel Amintas, Charline Caumont, Remi Veillon, Sigolene Galland-Girodet, Alain Cuguilliere, Laurent Nguyen, Charlotte Domblides, Amandine Gouverneur, Jean-Philippe Merlio, Julien Bezin, Pierre-Olivier Girodet
Summary: STK11 mutation is associated with poor prognosis in non-small cell lung cancer (NSCLC), leading to decreased response to immunotherapy treatment.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Cell Biology
Fabien Forest, David Laville, Cyril Habougit, Vanessa Da Cruz, Francois Casteillo, Violaine Yvorel, Sandrine Bard-Sorel, William Godard, Tiphanie Picot, Olivier Tiffet, Jean-Luc Perrot, Michel Peoc'h
Summary: The study analyzed 42 lung adenocarcinoma skin metastasis samples collected between 2010 and 2020 from a database of 2659 lung adenocarcinomas. The results showed that skin metastases of lung adenocarcinoma have a specific histopathological profile, indicating differences from other metastatic sites.
Article
Pathology
Yen-Lin Huang, Yi-Jung Chen, Yi-Hsiu Juan, Shang-Gin Wu, Kuei-Pin Chung
Summary: The phosphorylation of DRP1 is not related to the prognosis of patients with advanced lung adenocarcinoma.
PATHOLOGY RESEARCH AND PRACTICE
(2022)
Article
Multidisciplinary Sciences
Yumeng Wang, Huan Lin, Ningning Yao, Xiaobo Chen, Bingjiang Qiu, Yanfen Cui, Yu Liu, Bingbing Li, Chu Han, Zhenhui Li, Wei Zhao, Zimin Wang, Xipeng Pan, Cheng Lu, Jun Liu, Zhenbing Liu, Zaiyi Liu
Summary: In this study, an automated computational workflow was developed to evaluate the density of tertiary lymphoid structures (TLSs) in the tumor region of lung adenocarcinoma patients. The computerized TLS density was found to be associated with disease-free survival (DFS) and could improve prognostic stratification when combined with clinicopathological variables.
Article
Clinical Neurology
Haewon Roh, Sung Yong Lee, Jinhwan Lee, Soon -Young Hwang, Jong Hyun Kim
Summary: This study aims to investigate the prognostic relevance of various biomarkers of primary lung adenocarcinoma for clinical outcomes after stereotactic radiosurgery (SRS) in patients with brain metastases. The results showed that thyroid transcription factor 1 was an independent prognostic factor for local control, and napsin A was a significant predictor of overall survival after SRS.
JOURNAL OF NEUROSURGERY
(2022)
Article
Cell Biology
Takuo Hayashi, Monami Kishi, Kazuya Takamochi, Masaki Hosoya, Shinji Kohsaka, Satsuki Kishikawa, Ayako Ura, Kei Sano, Noriko Sasahara, Yoshiyuki Suehara, Fumiyuki Takahashi, Tsuyoshi Saito, Kenji Suzuki, Takashi Yao
Summary: A specific subtype of lung adenocarcinomas (LADs) characterized by TTF-1 expression arises from peripheral lung cells. The clinical relevance of other transcription factors (TFs) in LAD, besides TTF-1, is still unknown. The study revealed that PAX9, an endoderm development-associated TF, inversely correlates with TTF-1 expression and defines an aggressive subset of LADs occurring in smokers. PAX9-positive LADs are associated with heavy smoking, non-lepidic subtype, wild-type EGFR tumors, and PD-L1 expression.
Article
Oncology
Mi Jeong Hong, Ji Eun Park, Shin Yup Lee, Jang Hyuck Lee, Jin Eun Choi, Hyo-Gyoung Kang, Sook Kyung Do, Ji Yun Jeong, Kyung Min Shin, Won Ki Lee, Yangki Seok, Sun Ha Choi, Yong Hoon Lee, Hyewon Seo, Seung Soo Yoo, Jaehee Lee, Seung Ick Cha, Chang Ho Kim, Jae Yong Park
Summary: Genetic variants in miRNA target sites may affect the treatment outcome of pemetrexed chemotherapy in lung adenocarcinoma patients.
Article
Pathology
Kei Sano, Takuo Hayashi, Yoshiyuki Suehara, Masaki Hosoya, Kazuya Takamochi, Shinji Kohsaka, Satsuki Kishikawa, Monami Kishi, Satomi Saito, Fumiyuki Takahashi, Kazuo Kaneko, Kenji Suzuki, Takashi Yao, Muneaki Ishijima, Tsuyoshi Saito
Summary: In lung adenocarcinoma, different isoforms of NKX2-1/TTF-1 are encoded by multiple transcription start sites, with some isoforms associated with prognosis. The expression of certain isoforms, particularly those without exon 1, may define subsets of aggressive LAD in elder patients, indicating potential clinical implications.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH
(2021)
Article
Cell Biology
Yu-Chu Su, Yi-Cheng Chen, Yau-Lin Tseng, Gia-Shing Shieh, Pensee Wu, Ai-Li Shiau, Chao-Liang Wu
Summary: Oct4 is positively correlated with poor prognosis in lung adenocarcinoma patients by directly transactivating Stat1. Oct4 promotes tumor growth and apoptosis resistance by inducing Stat1 expression. Targeting the Oct4/Stat1/Mcl-1 axis may have therapeutic potential for lung adenocarcinoma.
Article
Medicine, General & Internal
Alice Court, David Laville, Sami Dagher, Vincent Grosjean, Pierre Dal-Col, Violaine Yvorel, Francois Casteillo, Sophie Bayle-Bleuez, Jean-Michel Vergnon, Fabien Forest
Summary: This retrospective study evaluated the value of anti-CK7 and anti-CK20 immunohistochemistry in suspected lung carcinoma biopsies. The results showed TTF-1 positivity in 73.3% of patients, with significant differences in EGFR mutations and ALK rearrangements between TTF-1 positive and TTF-1 negative tumors. TTF-1 negative carcinomas had a significantly shorter median survival. No specific pattern was found in the combination of CK7 and CK20 staining in TTF-1 negative patients.
Article
Oncology
Herdee Gloriane C. Luna, Marcelo Severino Imasa, Necy Juat, Katherine V. Hernandez, Treah May Sayo, Gloria Cristal-Luna, Sheena Marie Asur-Galang, Mirasol Bellengan, Kent John Duga, Bien Brian Buenaobra, Marvin I. De los Santos, Daniel Medina, Jamirah Samo, Venus Minerva Literal, Neil Andrew Bascos, Sullian Sy-Naval
Summary: TTF-1 expression varies significantly in non-small cell lung cancer, and high expression may be related to cell proliferation, immune evasion, and angiogenesis.
Article
Multidisciplinary Sciences
Igor Dolgalev, Hua Zhou, Nina Murrell, Hortense Le, Theodore Sakellaropoulos, Nicolas Coudray, Kelsey Zhu, Varshini Vasudevaraja, Anna Yeaton, Chandra Goparaju, Yonghua Li, Imran Sulaiman, Jun-Chieh J. Tsay, Peter Meyn, Hussein Mohamed, Iris Sydney, Tomoe Shiomi, Sitharam Ramaswami, Navneet Narula, Ruth Kulicke, Fred P. Davis, Nicolas Stransky, Gromoslaw A. Smolen, Wei-Yi Cheng, James Cai, Salman Punekar, Vamsidhar Velcheti, Daniel H. Sterman, J. T. Poirier, Ben Neel, Kwok-Kin Wong, Luis Chiriboga, Adriana Heguy, Thales Papagiannakopoulos, Bettina Nadorp, Matija Snuderl, Leopoldo N. Segal, Andre L. Moreira, Harvey I. Pass, Aristotelis Tsirigos
Summary: This study demonstrates that molecular profiling of tumor-adjacent tissue can predict disease progression in lung adenocarcinoma patients. The authors identified an inflammatory gene signature in tumor-adjacent tissue as the strongest clinical predictor of disease outcomes. Single-cell transcriptomic analysis showed that the progression-associated inflammatory signature was expressed in both immune and non-immune cells, and profiling of monocytes further improved outcome predictions.
NATURE COMMUNICATIONS
(2023)
Article
Respiratory System
Anne-Sophie Lamort, Jan Christian Kaiser, Mario A. A. Pepe, Ioannis Lilis, Giannoula Ntaliarda, Kalman Somogyi, Magda Spella, Sabine J. Behrend, Georgia A. Giotopoulou, Willem Kujawa, Michael Lindner, Ina Koch, Rudolf A. Hatz, Juergen Behr, Rocio Sotillo, Andrea C. Schamberger, Georgios T. Stathopoulos
Summary: Two molecular subtypes of LUAD have been identified, and their identification provides important prognostic information.
EUROPEAN RESPIRATORY JOURNAL
(2022)
Article
Oncology
Kazushi Fukagawa, Yu Takahashi, Nobutake Yamamichi, Natsuko Kageyama-Yahara, Yoshiki Sakaguchi, Miho Obata, Rina Cho, Nobuyuki Sakuma, Sayaka Nagao, Yuko Miura, Naoki Tamura, Daisuke Ohki, Hiroya Mizutani, Seiichi Yakabi, Chihiro Minatsuki, Keiko Niimi, Yosuke Tsuji, Mitsue Yamamichi, Narumi Shigi, Shuta Tomida, Hiroyuki Abe, Tetsuo Ushiku, Kazuhiko Koike, Mitsuhiro Fujishiro
Summary: In this study, the transcriptome analysis of GA-FG revealed significant expression of NKX2-1/TTF1 in GA-FG. Immunohistochemistry and cell biology experiments demonstrated ectopic expression and normal transactivation ability of NKX2-1/TTF-1, suggesting its essential role in GA-FG development.
Article
Biochemistry & Molecular Biology
Tingshan He, Jing Li, Peng Wang, Zhiqiao Zhang
Summary: This study developed an artificial intelligence predictive system for individual survival rate of lung adenocarcinoma (LUAD) and identified risk factors for LUAD patients. The predictive system utilized different data mining algorithms to provide individual survival curves and compare individual mortality risk curves under different treatments.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
(2022)
Article
Veterinary Sciences
Simone de Brot, Jennifer Lothion-Roy, Llorenc Grau-Roma, Emily White, Franco Guscetti, Mark A. Rubin, Nigel P. Mongan
Summary: The histomorphology and expression of neuroendocrine markers in canine prostate cancer show specific features, associated with inflammation and urothelial differentiation. The study reports for the first time the expression of the neuroendocrine marker NSE and the finding of intraductal carcinoma of the prostate in dogs with prostate cancer.
VETERINARY AND COMPARATIVE ONCOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Matthew J. Mosquera, Sungwoong Kim, Rohan Bareja, Zhou Fang, Shuangyi Cai, Heng Pan, Muhammad Asad, Maria Laura Martin, Michael Sigouros, Florencia M. Rowdo, Sarah Ackermann, Jared Capuano, Jacob Bernheim, Cynthia Cheung, Ashley Doane, Nicholas Brady, Richa Singh, David S. Rickman, Varun Prabhu, Joshua E. Allen, Loredana Puca, Ahmet F. Coskun, Mark A. Rubin, Himisha Beltran, Juan Miguel Mosquera, Olivier Elemento, Ankur Singh
Summary: This study defined the role of ECM signals in the development of CRPC-NEPC and identified potential therapeutic targets for neuroendocrine prostate cancer. In animal models, strong anti-tumor responses were observed with the use of a DRD2 inhibitor, and a combination of epigenetic inhibitors and DRD2 treatment was shown to overcome therapeutic resistance in CRPC-NEPC under drug-resistant ECM conditions.
ADVANCED MATERIALS
(2022)
Review
Oncology
Ursula M. Vogl, Tomasz M. Beer, Ian D. Davis, Neal D. Shore, Christopher J. Sweeney, Piet Ost, Gerhardt Attard, Alberto Bossi, Johann de Bono, Charles G. Drake, Eleni Efstathiou, Stefano Fanti, Karim Fizazi, Susan Halabi, Nicolas James, Nicolas Mottet, Anwar R. Padhani, Mack Roach, Mark Rubin, Oliver Sartor, Eric Small, Matthew R. Smith, Howard Soule, Matthew R. Sydes, Bertrand Tombal, Aurelius Omlin, Silke Gillessen
Summary: This article discusses the lack of consensus on clinical management issues in advanced prostate cancer addressed at the Advanced Prostate Cancer Consensus Conference. By reviewing ongoing clinical trials, it is found that many unresolved questions remain. The article emphasizes that the lack of consensus indicates gaps in existing evidence and calls for robust clinical trials to fill these gaps.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Urology & Nephrology
Fabio Turco, Andrew Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, Orazio Caffo, Kim N. Chi, Caroline Clarke, Noel Clarke, Ian D. Davis, Johann de Bono, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Jason Efstathiou, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Karim Fizazi, Mark Frydenberg, Dan George, Martin Gleave, Susan Halabi, Daniel Heinrich, Celestia Higano, Michael S. Hofman, Maha Hussain, Nicholas James, Rob Jones, Ravindran Kanesvaran, Raja B. Khauli, Laurence Klotz, Raya Leibowitz, Christopher Logothetis, Fernando Maluf, Robin Millman, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Hind Mrabti, Declan G. Murphy, Vedang Murthy, William K. Oh, Ngozi Ekeke Onyeanunam, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Christopher Parker, Darren M. C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Mark Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard Scher, Neal Shore, Iwona Skoneczna, Eric Small, Matthew Smith, Howard Soule, Daniel Spratt, Cora N. Sternberg, Hiroyoshi Suzuki, Christopher Sweeney, Matthew Sydes, Mary-Ellen Taplin, Derya Tilki, Bertrand Tombal, Levent Turkeri, Hiroji Uemura, Hirotsugu Uemura, Inge van Oort, Kosj Yamoah, Dingwei Ye, Almudena Zapatero, Silke Gillessen, Aurelius Omlin
Summary: This article discusses the optimal management of advanced prostate cancer patients during the COVID-19 pandemic. The study results indicate a consensus for full COVID-19 vaccination and booster injection, and the vaccination status influences the expert's treatment recommendations. Additionally, there is strong support for the use of telemedicine in monitoring patients.
Article
Oncology
Chantal Pauli, Lamberto De Boni, Jonathan E. Pauwels, Yanjiang Chen, Lara Planas-Paz, Reid Shaw, Brooke M. Emerling, Carla Grandori, Benjamin D. Hopkins, Mark A. Rubin
Summary: In this study, a functional precision oncology approach was implemented to identify tumor-specific drug sensitivities for patients with rare tumor types such as myxofibro-sarcoma. Comprehensive genomic profiling and high-throughput drug screening were used to identify therapeutic options and validate them in patient-derived xenograft models. Targeting the cell cycle was found to be a powerful approach in these tumors.
MOLECULAR CANCER RESEARCH
(2022)
Article
Medicine, Research & Experimental
Jacqueline Fontugne, Peter Y. Cai, Hussein Alnajar, Bhavneet Bhinder, Kyung Park, Huihui Ye, Shaham Beg, Verena Sailer, Javed Siddiqui, Mirjam Blattner-Johnson, Jaclyn A. Croyle, Zohal Noorzad, Carla Calagua, Theresa Y. MacDonald, Ulrika Axcrona, Mari Bogaard, Karol Axcrona, Douglas S. Scherr, Martin G. Sanda, Bjarne Johannessen, Arul M. Chinnaiyan, Olivier Elemento, Rolf Skotheim, Mark A. Rubin, Christopher E. Barbieri, Juan Miguel Mosquera
Summary: Prostate cancer is a multifocal disease with distinct molecular subtypes. This study reveals the presence of inter- and intrafocal molecular heterogeneity in primary prostate cancer, with approximately 60% of multifocal specimens showing discordant molecular alterations between foci. Collision tumors, characterized by discrepant molecular status within a single focus, are identified in about 10% of the specimens. These findings highlight the complexity of molecular heterogeneity in prostate cancer and have important implications for future genomic studies.
Review
Veterinary Sciences
Toby Ryman-Tubb, Jennifer H. Lothion-Roy, Veronika M. Metzler, Anna E. Harris, Brian D. Robinson, Albert A. Rizvanov, Jennie N. Jeyapalan, Victoria H. James, Gary England, Catrin S. Rutland, Jenny L. Persson, Lukas Kenner, Mark A. Rubin, Nigel P. Mongan, Simone de Brot
Summary: Prostate cancer is relatively rare in dogs but is the most common non-cutaneous cancer in men. Canine prostate cancer has been proposed as a model for understanding prostate cancer in men due to the similarities in functional, anatomical, and physiological features. The necessity to better understand the mechanisms of prostate cancer initiation and progression to develop novel therapeutic approaches is urgent, particularly in the context of castrate-resistant prostate cancer in men.
VETERINARY MEDICINE AND SCIENCE
(2022)
Article
Urology & Nephrology
Silke Gillessen, Andrew Armstrong, Gert Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Robert G. Bristow, Muhammad Bulbul, Orazio Caffo, Kim N. Chi, Caroline S. Clarke, Noel Clarke, Ian D. Davis, Johann S. de Bono, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Jason Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Karim Fizazi, Mark Frydenberg, Dan George, Martin Gleave, Susan Halabi, Daniel Heinrich, Celesta Higano, Michael S. Hofman, Maha Hussain, Nick James, Robert Jones, Ravindran Kanesvaran, Raja B. Khauli, Laurence Klotz, Raya Leibowitz, Chris Logothetis, Fernando Maluf, Robin Millman, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Hind Mrabti, Declan G. Murphy, Vedang Murthy, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Chris Parker, Darren M. C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Rob E. Reiter, Mark Rubin, Charles J. Ryan, Fred Saad, Juan P. Sade, Oliver Sartor, Howard Scher, Neal Shore, Iwona Skoneczna, Eric Small, Matthew Smith, Howard Soule, Daniel E. Spratt, Cora N. Sternberg, Hiroyoshi Suzuki, Christopher Sweeney, Matthew R. Sydes, Mary-Ellen Taplin, Derya Tilki, Bertrand Tombal, Levent Turkeri, Hiroji Uemura, Hirotsugu Uemura, Inge van Oort, Kosj Yamoah, Dingwei Ye, Almudena Zapatero, Aurelius Omlin
Summary: The voting results from the 2021 Advanced Prostate Cancer Consensus Conference provide guidance for clinicians and patients in the management of advanced prostate cancer where evidence is scarce. However, treatment decisions should be individualized based on patient characteristics and current clinical evidence.
Correction
Urology & Nephrology
Fabio Turco, Andrew Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, Orazio Caffo, Kim N. Chi, Caroline Clarke, Noel Clarke, Ian D. Davis, Johann de Bono, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Jason Efstathiou, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Karim Fizazi, Mark Frydenberg, Dan George, Martin Gleave, Susan Halabi, Daniel Heinrich, Celestia Higano, Michael S. Hofman, Maha Hussain, Nicholas James, Rob Jones, Ravindran Kanesvaran, Raja B. Khauli, Laurence Klotz, Raya Leibowitz, Christopher Logothetis, Fernando Maluf, Robin Millman, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Hind Mrabti, Declan G. Murphy, Vedang Murthy, William K. Oh, Onyeanunam Ngozi Ekeke, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Christopher Parker, Darren M. C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Mark Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Neal Shore, Iwona Skoneczna, Eric Small, Matthew Smith, Howard Soule, Daniel Spratt, Cora N. Sternberg, Hiroyoshi Suzuki, Christopher Sweeney, Matthew Sydes, Mary-Ellen Taplin, Derya Tilki, Bertrand Tombal, Levent Turkeri, Hiroji Uemura, Hirotsugu Uemura, Inge van Oort, Kosj Yamoah, Dingwei Ye, Almudena Zapatero, Silke Gillessen, Aurelius Omlin
Article
Oncology
Joanna Cyrta, Davide Prandi, Arshi Arora, Daniel H. Hovelson, Andrea Sboner, Antonio Rodriguez, Tarcisio Fedrizzi, Himisha Beltran, Dan R. Robinson, Anuradha Gopalan, Lawrence True, Peter S. Nelson, Brian D. Robinson, Juan Miguel Mosquera, Scott A. Tomlins, Ronglai Shen, Francesca Demichelis, Mark A. Rubin
Summary: This study compares the pathological and molecular features of primary prostate cancer (PCa) and metastases, revealing their heterogeneity. The results highlight the importance of comprehensive immunohistochemistry-assisted pathology review and genomic analysis in determining the "index" area of primary PCa.
JOURNAL OF PATHOLOGY
(2022)
Review
Endocrinology & Metabolism
Kellie Cotter, Mark A. Rubin
Summary: In recent years, the landscape of somatic mutations in prostate cancer (PCa) has rapidly evolved with the improvement in genomic sequencing platforms. However, there are still limitations in the current knowledge, such as low coverage and incomplete coverage of the mutation spectrum. Some alterations require DNA and RNA analysis for accurate frequency detection, and most studies rely on bulk PCa tumor samples without considering tumor heterogeneity.
Article
Pathology
Andrew Janowczyk, Daniel Baumhoer, Stefan Dirnhofer, Rainer Grobholz, Anja Kipar, Laurence de Leval, Doron Merkler, Olivier Michielin, Holger Moch, Aurel Perren, Sven Rottenberg, Laura Rubbia-Brandt, Mark A. Rubin, Christine Sempoux, Markus Tolnay, Inti Zlobec, Viktor Hendrik Koelzer
Summary: Precision medicine is advancing into a new era of digital diagnostics, with the potential for integrated digital pathology and clinical data to drive biomedical research and business development. The creation of a Swiss Digital Pathology Infrastructure aims to establish a unified national network and facilitate international research collaboration, ultimately improving patient care through precision medicine.
Review
Oncology
Dilara Akhoundova, Mark A. Rubin
Summary: Next-generation DNA sequencing technology has greatly advanced clinical oncology by identifying therapeutic targets and molecular biomarkers, leading to personalized cancer treatment. Recent developments in tumor profiling now enable us to understand the molecular architecture and functional phenotype of tumors at the cellular and subcellular resolution.
Article
Oncology
Alison M. Ferguson, Mark A. Rubin
Summary: The emergence of small cell prostate cancer is associated with tumor cell plasticity and evasion of environmental pressures. In-depth understanding of tumor plasticity can be achieved through clinical cohorts and disease progression models. Studying the tumor microenvironment and earlier time points can provide a comprehensive understanding and potentially lead to better patient outcomes by intervening early to reverse plasticity and prevent transition to the aggressive small cell phenotype.
Article
Oncology
Carolyn C. Compton, Angelo M. De Mario, Jayanta Debnath, Keith D. Eaton, Kojo Elenitoba-Johnson, Michelangelo Fiorentino, Christopher A. French, Thomas J. Fuchs, Felice Giangaspero, Jiaoti Huang, A. John Lafrate, Michael M. Ittmann, Roy A. Jensen, Annette S. Kim, Massimo Loda, Robin G. Lorenz, Tamara L. Lotan, Anirban Maitre, Gerrit A. Meijer, Richard N. Mitchell, Anil Parwani, Francesco Pezzella, Eli Pikarsky, Jorge S. Reis-Filho, Andrea L. Richardson, Mark A. Rubin, Lawrence D. True
Summary: This article highlights the crucial role of pathologists in oncology practice and cancer research, focusing on their involvement in a patient's journey in cancer care.
CLINICAL CANCER RESEARCH
(2022)